Publications:  Dr Jessica Okosun

Kumar EA, Okosun J, Fitzgibbon J(2020). The Biological Basis of Histologic Transformation. Hematology/Oncology Clinics of North America vol. 34, (4) 771-784.

Araf S, Korfi K, Bewicke-Copley F, Wang J, Cogliatti S, Kumar E, Forrer F, Barrington SF et al.(2020). Genetic heterogeneity highlighted by differential FDG-PET response in diffuse large B-cell lymphoma. Haematologica vol. 105, (6) E318-E321.

Aries JA, Davies JK, Auer RL, Hallam SL, Montoto S, Smith M, Sevillano B, Foggo V et al.(2020). Clinical Outcome of Coronavirus Disease 2019 in Haemato-oncology Patients. British Journal of Haematology

Krysov S, Odabashian M, Carlotti E, Araf S, Okosun J, Spada F, Gribben J, Forconi F et al.(2020). IGHV sequencing reveals acquired N-glycosylation sites as a clonal and stable event during follicular lymphoma evolution. Blood vol. 135, (11) 834-844.

Okosun J, Montoto S(2020). Cellular Therapy in Follicular Lymphoma: Autologous Stem Cell Transplantation, Allogeneic Stem Cell Transplantation, and Chimeric Antigen Receptor T-cell Therapy. Hematology/Oncology Clinics of North America

Matasar MJ, Luminari S, Barr PM, Barta SK, Danilov AV, Hill BT, Phillips TJ, Jerkeman M et al.(2019). Follicular Lymphoma: Recent and Emerging Therapies, Treatment Strategies, and Remaining Unmet Needs. Oncologist vol. 24, (11) e1236-e1250.

Ortega-Molina A, Deleyto-Seldas N, Carreras J, Sanz A, Lebrero-Fernández C, Menéndez C, Vandenberg A, Fernández-Ruiz B et al.(2019). Oncogenic Rag GTPase signalling enhances B cell activation and drives follicular lymphoma sensitive to pharmacological inhibition of mTOR. Nature Metabolism vol. 1, (8) 775-789.

Araf S, Wang J, Korfi K, Pangault C, Kotsiou E, Rio-Machin A, Rahim T, Heward J et al.(2019). Correction: Genomic profiling reveals spatial intra-tumor heterogeneity in follicular lymphoma (Leukemia, (2018), 32, 5, (1261-1265), 10.1038/s41375-018-0043-y). Leukemia vol. 33, (6)

Araf S, Wang J, Ashton-Key M, Korfi K, Di Bella D, Rio-Machin A, Odabashian M, Foria V et al.(2019). Transmission of diffuse large B-cell lymphoma by an allogeneic stem-cell transplant. Haematologica vol. 104, (4) e174-e177.

Okosun J, Kridel R, Fitzgibbon J(2018). Rituximab as a first step in tackling transformation. The Lancet Haematology vol. 5, (8) e326-e327.

Heward JA, Kumar EA, Korfi K, Okosun J, Fitzgibbon J(2018). Precision medicine and lymphoma. Curr Opin Hematol vol. 25, (4) 329-334.

Araf S, Wang J, Korfi K, Pangault C, Kotsiou E, Rio-Machin A, Rahim T, Heward J et al.(2018). Genomic profiling reveals spatial intra-tumor heterogeneity in follicular lymphoma. Leukemia vol. 32, (5) 1258-1263.

Araf S, Okosun J, Fitzgibbon J(2018). Predicting early relapse in follicular lymphoma: have we turned a corner?. The Lancet Oncology vol. 19, (4) 441-442.

Horton SJ, Giotopoulos G, Yun H, Vohra S, Sheppard O, Bashford-Rogers R, Rashid M, Clipson A et al. (2017). Early loss of Crebbp confers malignant stem cell properties on lymphoid progenitors. Nature Cell Biology. vol. 19, 1093-1104.

Larrea E, Fernandez-Mercado M, Ceberio I, Assuncao JAG, Okosun J, Fitzgibbon J, Lawrie C (2017). RECURRENT MUTATIONS IN MICRO-RNA BINDING SITES MAY BE POTENTIALLY RELEVANT IN FOLLICULAR LYMPHOMA. HAEMATOLOGICA. vol. 102, 94-95.

Mansouri L, Noerenberg D, Young E, Mylonas E, Abdulla M, Frick M, Asmar F, Ljungström V et al.(2016). Frequent NFKBIE deletions are associated with poor outcome in primary mediastinal B-cell lymphoma. Blood vol. 128, (23) 2666-2670.

Araf S, Wang J, Pangault C, Kotsiou E, Hoxha E, Iqbal S, Davies J, Johnson P et al. (2016). GENOMIC PROFILING REVEALS SPATIAL HETEROGENEITY IN FOLLICULAR LYMPHOMA: IMPLICATIONS FOR PRECISION MEDICINE. HAEMATOLOGICA. vol. 101, 270-270.

Okosun J, Montoto S, Fitzgibbon J(2016). The routes for transformation of follicular lymphoma. Current Opinion in Hematology vol. 23, (4) 1-1.

Kotsiou E, Okosun J, Besley C, Iqbal S, Matthews J, Fitzgibbon J, Gribben J, DAVIES JK(2016). TNFRSF14 aberrations in follicular lymphoma increase clinically significant allogeneic T-cell responses. Blood vol. 128, (1) 72-81.

Okosun J, Wolfson RL, Wang J, Araf S, Wilkins L, Castellano BM, Escudero-Ibarz L, Al Seraihi AF et al.(2016). Recurrent mTORC1-activating RRAGC mutations in follicular lymphoma. Nature Genetics vol. 48, (2) 183-188.

Araf S, Okosun J, Koniali L, Fitzgibbon J, Heward J(2016). Epigenetic dysregulation in follicular lymphoma. Epigenomics vol. 8, (1) 77-84.

Okosun J, Cwynarski K(2015). Non-Hodgkin Lymphoma: High Grade. Postgraduate Haematology: Seventh Edition,

Tawana K, Wang J, Renneville A, Bödör C, Hills R, Loveday C, Savic A, Van Delft FW et al.(2015). Disease evolution and outcomes in familial AML with germline CEBPA mutations. Blood vol. 126, (10) 1214-1223.

Okosun J, Packham G, Fitzgibbon J(2014). Investigational epigenetically targeted drugs in early phase trials for the treatment of haematological malignancies. Expert Opinion on Investigational Drugs vol. 23, (10) 1321-1332.

Okosun J, Bödör C, Wang J, Araf S, Yang CY, Pan C, Boller S, Cittaro D et al.(2014). Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma. Nature Genetics vol. 46, (2) 176-181.

Popov N, Maniati E, Marzec J, Okosun J, Scott R, Kranz A, Stewart F, Chelala C et al. (2013). Investigating The Role Of MLL2 (Mll4) In B Cell Development. BLOOD. vol. 122,

Okosun J, Clear A, Iqbal S, Matthews J, Gribben J, Fitzgibbon J, Davies J (2013). TNFRSF14 aberrations are associated with death from acute GvHD after reduced-intensity conditioned allogeneic haematopoietic stem cell transplantation for follicular lymphoma. BONE MARROW TRANSPLANTATION. vol. 48, S169-S169.

Bödör C, Grossmann V, Popov N, Okosun J, O¿Riain C, Tan K, Marzec J, Araf S et al.(2013). EZH2 mutations are frequent and represent an early event in follicular lymphoma. Blood vol. 122, (18) 3165-3168.

Montoto S, Shaw K, Okosun J, Gandhi S, Fields P, Wilson A, Shanyinde M, Cwynarski K et al.(2012). HIV status does not influence outcome in patients with classical Hodgkin lymphoma treated with chemotherapy using doxorubicin, bleomycin, vinblastine, and dacarbazine in the highly active antiretroviral therapy era. Journal of Clinical Oncology vol. 30, (33) 4111-4116.

Okosun J, Warbey V, Shaw K, Montoto S, Fields P, Marcus R, Virchis A, McNamara C et al.(2012). Interim fluoro-2-deoxy-D-glucose-PET predicts response and progression-free survival in patients with Hodgkin lymphoma and HIV infection. AIDS vol. 26, (7) 861-865.

Orkin C, Montoto S, Shaw K, Okosun J, Gandhi S, Fields P, Wilson A, Shanyinde M et al.(2012). HIV Status does not Impact on Outcome in Patients with Hodgkin Lymphoma Treated with ABVD Chemotherapy in the HAART Era. HIV MEDICINE vol. 13, 5-5.

Okosun J, Bödör C, Smith M(2011). Myelodysplastic syndrome: 2011 and beyond. British Journal of Nursing vol. 20, (22)

Montoto S, Shaw K, Okosun J, Gandhi S, Fields P, Wilson A, Shanyinde M, Cwynarski K et al. (2011). HIV Status Does Not Impact on Outcome in Patients with Hodgkin Lymphoma Treated with ABVD Chemotherapy in the HAART Era. BLOOD. vol. 118, 1557-1557.

Okosun J, Fitzgibbon J(2011). It's a targeted world in non-Hodgkin's lymphoma. Br J Nurs vol. 20, (17)

Okosun J, Fitzgibbon J(2011). It's a targeted world in non-Hodgkin's lymphoma. British Journal of Nursing vol. 20, (17 SUPPL.)

Okosun J, Mwirigi A, Kyriakou C, Cwynarski K, Hughes D, Fields P, Mcnamara C (2011). PROGNOSTIC SIGNIFICANCE OF RESPONSE QUALITY (RQ) IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA (FL) PATIENTS TREATED WITH COMBINATION RITUXIMAB, CYCLOPHOSPHAMIDE, VINCRISTINE AND PREDNISOLONE (R-CVP). ANNALS OF ONCOLOGY. vol. 22, 218-218.

Okosun J, McNamara C(2011). Paraneoplastic peripheral blood eosinophilia in relapsed follicular lymphoma. Leukemia and Lymphoma vol. 52, (2) 328-330.

Bower M, Montoto S, Cwynarski K, Lumsden AS, Rajab R, Okosun J, Orkin C, Nelson M et al.(2010). Non-germinal centre subtype of AIDS-related diffuse large B-cell lymphomas associated with improved survival. HIV MEDICINE vol. 11, 13-13.